Cytosorbents Corp Received its Third Buy in a Row

By Jason Carr

After Maxim Group and H.C. Wainwright assigned a Buy rating to Cytosorbents Corp in the last month, the company received another Buy, this time from Aegis Capital. Analyst Difei Yang reiterated a Buy rating on Cytosorbents Corp (NASDAQ: CTSO) today and set a price target of $9. The company’s shares opened today at $4.40, close to its 52-week low of $3.95.

According to TipRanks.com, Yang is a 4-star analyst with an average return of 7.1% and a 46.3% success rate. Yang covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Protalix Biotherapeutics, and Spectrum Pharmaceuticals.

Currently, the analyst consensus on Cytosorbents Corp is Strong Buy and the average price target is $10.67, representing a 142.5% upside.

In a report issued on May 22, Maxim Group also reiterated a Buy rating on the stock with a $10 price target.

The company has a one year high of $6.90 and a one year low of $3.95. Currently, Cytosorbents Corp has an average volume of 163.2K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CytoSorbents Corp. is a critical care immunotherapy company, which engages in blood purification to control deadly inflammation in critically-ill and cardiac surgery patients. Its products include cytosorb, contrastsorb, vetresq, hemodefend, and drugsorb. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Monmouth Junction, NJ.